September 12, 2016 / 12:17 PM / a year ago

BRIEF-Aptose submits formal response to clinical hold for APTO-253

Sept 12 (Reuters) - Aptose Biosciences Inc

* During a phase 1b clinical trial with APTO-253, a clinical site experienced stoppage of infusion pump during an iv infusion

* Submitted formal response to U.S. FDA regarding previously announced clinical hold of aptose’s phase 1b clinical trial of APTO-253

* Says stoppage of infusion pump during an iv infusion caused by back pressure as a result of clogging of in-line filter

* During a phase 1b clinical trial with APTO-253, a clinical site experienced stoppage of infusion pump during an iv infusion

* Says co provided responses to all of questions cited in clinical hold letter issued by FDA

* Based issue with molecule

* Says now working with a drug product that does not cause filter clogging or pump stoppage

* Now working with drug product that does not cause filter clogging or pump stoppage during mock infusion studies Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below